Syndrome in Medical Technology

Lexicon's Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA

THE WOODLANDS, Texas, July 21 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has received orphan d...

Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation

-- Data Presented Today at DDW Demonstrate Linaclotide Provided Early Onset of Abdominal Pain Relief and Improved Bowel Habits -- CAMBRIDGE, Mass. and NEW YORK, May 31, 2009 /PRNewswire-FirstCall/ -- Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. (NYSE: FRX ) today announced r...

New Study Shows Probiotic Strain Effective in Improving Irritable Bowel Syndrome Symptoms

Bacillus coagulans significantly reduces abdominal pain and bloating CLEVELAND, March 24 /PRNewswire/ -- A new study published in the March issue of Postgraduate Medicine found that a strain of probiotic bacteria, Bacillus coagulans GBI-30, PTA-6086 was effective in relieving abdominal ...

Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease

HAYWARD, Calif., March 24 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that after completing its review of safety and efficacy data from the first cohort of 30 patients, an independent Data S...

Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting

THE WOODLANDS, Texas, March 5 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that Dr. Philip Brown , senior vice president of clinical develop...

Lenetix Launches Screening Study of New Down Syndrome Test

MINEOLA, N.Y., Feb. 5 /PRNewswire/ -- Lenetix, Inc. today announced the launch of an Institutional Review Board (IRB)-approved screening study of an improved first and second trimester non-invasive fetal diagnostic test to detect Down syndrome. The Lenetix PloidYX(TM) maternal blood test promi...

Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation

- Data Presented Today at ACG Annual Scientific Meeting - ORLANDO, Fla., Oct. 7 /PRNewswire-FirstCall/ -- Ironwood Pharmaceuticals, Inc. (formerly Microbia, Inc.) and Forest Laboratories, Inc. (NYSE: FRX ) today announced the presentation of results from a Phase 2b study assessing lina...

VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial

- Top-line Data to be Released Concurrent with November 9 AHA Data Presentations - SAN FRANCISCO, Sept. 24 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a biotechnology company focused on the development of compounds for the treatment of ca...

Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial

SAN MATEO, Calif., Aug. 25 /PRNewswire/ -- Anthera Pharmaceuticals Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, today announced the initiation of the FRANCIS (Fewer Recurrent Acute coronary events with Near-term Cardiovascular Inflammation Suppression) c...

Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of 'Mr. C' Causes Major Interest in the Scientific Community

Study findings offer hope for increased life expectancy for people with Down syndrome WASHINGTON, Aug. 18 /PRNewswire-USNewswire/ -- In the world of Down syndrome, 'Mr. C' is a rarity. A real person whose progress has been tracked for the past 16 years, at seventy, 'Mr. C' has well surpassed...

New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C)

Additional Digestive Disease Week data highlight effects of AMITIZA in patients with IBS-C SAN DIEGO, May 18 /PRNewswire/ -- New study results indicated that treatment with AMITIZA(R) (lubiprostone) 8 mcg lead to significant relief of overall symptoms of Irritable Bow...

VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial

- Top Line Data Expected soon after CEA Trial data reports in third quarter - SAN FRANCISCO, May 15 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a biotechnology company focused on the development of compounds for the treatment of cardiov...

NAFLD AND NASH Linked to Metabolic Syndrome and Cardiovascular Disease

Patients With Fatty Liver are at Increased Risk of Cardiovascular Disease Prevalence Estimates Vary Widely, and Approach 25% Among Adults Risk Factors for Fatty Liver Include Overweight, Type 2 Diabetes, and Sedentary Lifestyle MILAN, April 24 /PRNewswire/ -- Data...

DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease

SAN MATEO, Calif., April 16 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that after completing its review of safety and efficacy data currently available, an independent Data Safety Monitoring Boar...

Recent Data Study Suggests Cortisol Could Help Alleviate Suffering for Those With Chronic Fatigue Syndrome and Fibromyalgia

New Hope Available for the Millions Suffering from these Diseases LOS ANGELES, March 19 /PRNewswire-USNewswire/ -- Chronic fatigue syndrome (CFS) and fibromyalgia (FM) are two serious and debilitating diseases with no confirmed cause and limited treatment options. However, results of a new ...

Anthera's A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease

SAN MATEO, Calif., Dec. 18 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Product Development has granted A-001 orphan drug status fo...

Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned

PARIS, Oct. 21 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted approval for a Supplemental New Drug Application (sNDA) for the indication of "Acute coronary syndrome (unstable angina pectoris, non-ST elevation ...

Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study

Conference Call Today at 9 am ET BEDMINSTER, N.J., Oct. 11 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP ) today reported top-line results from the company's Phase 3 study of its investigational drug GATTEX(TM) (teduglutide, recombinant GLP-2) in which ...

Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome

PALO ALTO, Calif., Aug. 3 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK ) today announced that the positive results from a Phase 1 multicenter, dose escalation study of ezatiostat hydrochloride (TELINTRA, TLK199) tablets in patients with Myelodysplastic Syndrome (MDS) have been p...

Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome

AIEA, Hawaii, July 20 /PRNewswire/ -- The Centers for Disease Control and Prevention reported this week that the prevalence of obesity among Americans is now over 26%. Obesity exacerbates a constellation of diseases including diabetes, liver disease, and heart disease, often in...

Anthera's Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome

- Favorable results for secondary endpoints support outcomes benefit HAYWARD, Calif., May 6 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that FRANCIS (Fewer Recurrent Acute coronary events ...

BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome

NOVATO, Calif., April 21 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced today the initiation of a Phase 1/2 clinical trial for BMN-110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosi...

Breakthrough in Prenatal Screening for Down Syndrome

Lenetix Announces Successful Study of Improved Non-invasive Test Procedure MINEOLA, N.Y., Jan. 28 /PRNewswire/ -- Lenetix, Inc. today announced a significant step in the development of an improved first and second trimester non-invasive fetal chromosomal screening test to detect Down syndrome...

Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome

- Results Presented at ASH Annual Meeting- SAN FRANCISCO, Dec. 6 /PRNewswire-FirstCall/ -- Sanofi-aventis today announced results of a randomized phase III study presented at the 50th Annual Meeting of the American Society of Hematology. The study in adult patients with hematological mali...

QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome

Pivotal Study Seeks to Enroll 750 Women at More Than 100 Sites in the U.S. ANN ARBOR, Mich., Sept. 4 /PRNewswire/ -- QuatRx Pharmaceuticals, a privately-held biopharmaceutical company focused on development and commercialization of compounds to treat endocrine, metabolic and cardiovascular diso...

Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men With Type 2 Diabetes and Metabolic Syndrome

New Data Highlights the Need for Testosterone Screening in At-Risk Hypogonadal Men BEDMINSTER, N.J., June 17 /PRNewswire/ -- New data from a 12-month, international, multi-center study showed that treatment for low testosterone with Tostran(R), a topical, metered ...

Tioga Pharmaceuticals' Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome

Statistically Significant Reduction of IBS Pain and Normalizing Motility Effect Observed SAN DIEGO, May 20 /PRNewswire/ -- Tioga Pharmaceuticals, Inc. today announced the results of a recent Phase 2b study of its oral kappa opioid receptor agonist, asimadoline, which...

Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome

Additional Data Demonstrate Predictable, Extended Exposure with Sustained- Release Formulation CHICAGO, April 17 /PRNewswire/ -- Data from the first pivotal study of XP13512/GSK1838262, a sustained-release investigational compound to treat Restless Legs Syndrome (RLS), ...

QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome

Novel non-estrogen oral therapy in development for menopausal symptoms ANN ARBOR, Mich., Jan. 3 /PRNewswire/ -- QuatRx Pharmaceuticals Company today announced positive results from a pivotal Phase 3 study of Ophena(TM) (ospemifene) to treat postmenopausal women with vulvovaginal atrophy, a co...

Obesity-Related Hormone is Higher in Children with Down Syndrome

PHILADELPHIA, Oct. 26 /PRNewswire-USNewswire/ -- Children with Down syndrome are more likely than their unaffected siblings to have higher levels of a hormone associated with obesity, according to pediatric researchers. The hormone, leptin, may contribute to the known higher risk of obesity am...

VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome

- Third Trial to Utilize FDG-PET Imaging - SAN FRANCISCO, Oct. 25 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals (Nasdaq: VIAP ), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it will soon initia...

Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome

PHILADELPHIA and THE WOODLANDS, Texas, Oct. 15 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ) presented data regarding Phase 1 clinical trial results for LX1031 at the annual meeting of the American College of Gastroenterology in Philadelphia, Pennsylvania. The studie...

Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome

- Data Presented at the 132nd Annual Meeting of the American Neurological Association in Washington, D.C. - ATLANTA, Oct. 8 /PRNewswire/ -- UCB, Inc. presented results from two Phase III pivotal trials and one open-label extension trial of rotigotine transdermal system for the...

Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome

Treatment with Norditropin increases gain in height for girls with Turner syndrome PRINCETON, N.J., Sept. 21 /PRNewswire-FirstCall/ -- Novo Nordisk today announced that Norditropin(R) (somatropin [rDNA origin] injection) received approval from the U.S. Food and Dr...

Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome

Treatment with Norditropin increases gain in height for girls with Turner syndrome PRINCETON, N.J., Sept. 21 /PRNewswire-FirstCall/ -- Novo Nordisk today announced that Norditropin(R) (somatropin [rDNA origin] injection) received approval from the U.S. Food and Dr...

QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome

Multicenter Study Enrolls More Than 800 Women to Evaluate QuatRx's New-Generation Selective Estrogen Receptor Modulator (SERM) ANN ARBOR, Mich., Aug. 22 /PRNewswire/ -- QuatRx Pharmaceuticals, a privately-held biopharmaceutical company focused on development and commercialization of co...

Hollis-Eden Announces Cancellation of Acute Radiation Syndrome RFP by Department of Health and Human Services

SAN DIEGO--(BUSINESS WIRE)--Mar 8, 2007 - Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) today announced that it was informed late Wednesday, March 07, 2007, by the Department of Health & Human Services (HHS) that NEUMUNE(R), the Company's product candidate for the treatment of Acute Radiation...

Study Presented at the ACC Shows Inflammatory Enzyme Lp-PLA2 Predicts Heart Disease Risk in Metabolic Syndrome Patients

NEW ORLEANS--(BUSINESS WIRE)--Mar 26, 2007 - Study results show that elevated lipoprotein-associated phospholipase A2 (Lp-PLA2), a cardiovascular-specific inflammatory enzyme associated with unstable plaque that can lead to heart attack and stroke, is especially predictive of heart disease risk in ...

Lipitor Provides Unprecedented Cardiovascular Risk Reductions in Diabetes Patients with Metabolic Syndrome and in Stroke Patients

NEW ORLEANS--(BUSINESS WIRE)--Mar 26, 2007 - Pfizer announced today that Lipitor(R) (atorvastatin calcium) Tablets 10 mg provided a significant 61 percent reduction in stroke in patients with type 2 diabetes and metabolic syndrome but without heart disease. In a separate study, patients who had suf...

Insmed Releases Positive Results from Iplex Phase II HIV-Associated Adipose Redistribution Syndrome Clinical Study

RICHMOND, Va.--(BUSINESS WIRE)--Apr 30, 2007 - Insmed Inc., (Nasdaq:INSM) today announced positive results from a Phase II investigator-sponsored clinical study of the company's drug IPLEX(TM) in HIV-infected patients affected with HIV-associated Adipose Redistribution Syndrome (HARS). Preliminary...